Drug
Nnc9204 1513
Nnc9204 1513: highest development phase Phase 1, developed by Novo Nordisk. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Novo Nordisk
Trials
| Drug | Phase | Indication |
|---|---|---|
| NNC9204-1513 NCT03444467 | Phase 1 | Diabetes |
Latest
No recent events.
Follow Nnc9204 1513 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.